

**IN THE CLAIMS:**

Please amend the claims as shown in the following listing of claims. This listing of claims will replace all prior versions, and listings, of claims in the application:

1-26 (Cancelled)

27. (Currently Amended) A method for achieving full occlusion[[ding]] of a vascular vessel, comprising delivering to the vessel an embolization device comprising a harvested submucosal tissue so as to ~~occlude~~ and cause a full occlusion and full blockage of the vascular vessel.

28. (Original) The method of claim 27, wherein the embolization devices comprises a coil.

29. (Original) The method of claim 27, wherein the submucosa is porcine submucosa.

30. (Original) The method of claim 27, wherein the embolization device comprises at least one sheet of submucosa.

31. (Previously Presented) The method of claim 27, wherein the device comprises a particulate material comprising submucosa.

32. (Currently Amended) A method for achieving full occlusion[[ding]] of a vascular vessel of a patient, comprising delivering to the vessel an embolization device comprising a harvested remodelable collagenous extracellular matrix biomaterial so as to ~~occlude~~ and cause a full occlusion and full blockage of the vascular vessel, wherein the harvested remodelable collagenous extracellular matrix biomaterial is effective to promote a healing response in an area of the vascular vessel occluded with the harvested remodelable collagenous extracellular matrix biomaterial.

33. (Previously Presented) The method of claim 32, wherein the biomaterial comprises submucosa.

34. (Previously Presented) The method of claim 32, wherein the device comprises a coil.

35. (Previously Presented) The method of claim 32, wherein the biomaterial comprises porcine submucosa.

36. (Previously Presented) The method of claim 32, wherein the device comprises at least one sheet of the remodelable collagenous extracellular matrix biomaterial.

37. (Previously Presented) The method of claim 32, wherein a pharmacologic agent is disposed on the biomaterial.

38. (Previously Presented) The method of claim 32, wherein the biomaterial comprises at least one of a brush-like, braided, branched, coil, cubic, cylindrical, helical, injectable, layered, randomized, sheet-like, spherical, and tubular component .

39. (Previously Presented) The method of claim 32, wherein the biomaterial further comprises at least one of a growth factor, protein, proteoglycan, glycoprotein, glycosaminoglycan, physiological compatible mineral, antibiotic, chemotherapeutic agent, enzyme, pharmaceutical, taxol, taxol derivative, genetic material, and hormone.

40. (Previously Presented) The method of claim 32, wherein the biomaterial comprises a material selected from submucosa, pericardium, basement membrane, and amniotic membrane.

41. (Previously Presented) The method of claim 32, wherein the biomaterial also comprises a radiopaque marker.

42. (Previously Presented) The method of claim 32, wherein the biomaterial is injectable.

43. (Previously Presented) The method of claim 32, wherein the biomaterial is in comminuted form.

44. (Previously Presented) The method of claim 33, wherein the biomaterial is in comminuted form.